Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 8/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23574107 | 1.00 | USP30 (0.44) | USP30NAAAGRM5MAPTUCHL1 | |
| SCHEMBL23574110 | 1.00 | USP30 (0.44) | USP30NAAAGRM5MAPTUCHL1 | |
| SCHEMBL23574006 | 0.86 | USP30 (0.48) | USP30UCHL1 | |
| SCHEMBL23574007 | 0.86 | USP30 (0.48) | USP30UCHL1 | |
| SCHEMBL23574115 | 0.86 | USP30 (0.41) | USP30MAPTALDH1A1 | |
| SCHEMBL23113722 | 0.86 | USP30 (0.41) | USP30MAPTALDH1A1 | |
| SCHEMBL23113721 | 0.86 | USP30 (0.41) | USP30MAPTALDH1A1 | |
| SCHEMBL23574028 | 0.86 | USP30 (0.49) | USP30 | |
| SCHEMBL23574035 | 0.86 | USP30 (0.49) | USP30 | |
| SCHEMBL23574030 | 0.86 | USP30 (0.49) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | claimed |
| EP-3793997-B1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-03-13 | — | — | EP | claimed |
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | USP30, UCHL1, ADRM1 | USP30 1/4885NAAA 3034/4885GRM5 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.